Pharmaceutical composition for treating cardiovascular diseases and preparation method and use thereof

A composition and cardiovascular technology, applied in the direction of cardiovascular system diseases, drug combinations, pharmaceutical formulas, etc., can solve undiscovered problems, reduce adverse reactions, improve antihypertensive effect, and reduce the number of times of taking
CN101690725AInactive Publication Date: 2010-04-07GUANGXI FANGLUE GROUP LONGZHOU PHARMA
51 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
GUANGXI FANGLUE GROUP LONGZHOU PHARMA
Publication Date
2010-04-07
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a pharmaceutical composition containing eprosartan, amlodipine and hydrochlorothiazide and a prepration method and a use thereof, the composition consists of the eprosartan, the amlodipine and the hydrochlorothiazide, and the composition is used for treating patients with moderate hypertension, severe hypertension, coronary heart disease and angina and the patients with the hypertension, the coronary heart disease and the angina, wherein blood pressure of the patients can not be fully controlled after using an angiotensin II receptor antagonist or a calcium antagonist for treating.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a pharmaceutical composition for treating cardiovascular disease and a preparation method thereof, in particular to the pharmaceutical composition prepared with eprosartan, the calcium antagonist amlodipine and the diuretic hydrochlorothiazide and its application. Background technique

[0002] Eprosartan is an angiotensin II receptor antagonist, and its mesylate is mainly used clinically. Its chemical name is: 4-[[2-butyl-5-(2-formyl-3-thiophen-2-yl-propen-1-yl)-imidazol-1-yl]methyl]benzoic acid methanesulfonate acid salt, its molecular formula is: C 23 h 24 N 2 o 4 SCH 4 o 3 S, its molecular weight is: 520.62, and its structural formula is:

[0003]

[0004] Eprosartan was first launched in Germany in 1998. In the United States, eprosartan is the fastest-growing type of hypertension in the market, with annual sales of about 2.6 billion U.S. dollars and an annual growth rate of 34%. Eprosartan is an angiotensin II r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More